EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

Overview of attention for article published in Journal of Clinical Oncology, February 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 2 news outlets
policy: 1 policy source
twitter: 12 X users

patent: 1 patent
guideline: 1 clinical guideline source
podcasts: 2 podcasts

Readers on

mendeley: 210 Mendeley

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 135,735 followers.

Exposure plots from EV multi-descipline review. Other links: Phase 1 data (see also supplementary!): https://t.co/cVKmeSTYuU Correlation of skin tox, single-center experience, ORR: https://t.co/yDJUuv2iqT This most recent paper, with PFS and OS:…

EV-Pembro is SOC for 1st line bladder cancer 50% of pts -> neuropathy Note phase 1 of EV monoRx 1mg/kg cohort: neuropathy 19%, ORR 19% 1.25mg/kg cohort: neuropathy 38%, ORR 43% Lesson: Don't dose reduce EV upfront @DrRosenbergMSK @DanielPetryl…

RT @ASCO_pubs: Enfortumab vedotin in Nectin-4-positive solid tumors including metastatic urothelial carcinoma https://t.co/nPZ9M4x3QW #uroo…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.